The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Selecting appropriate first line lung cancer therapy

Bookmark and Share

AACR 2009

18 - 22 Apr 2009

Please rate this video

The information in this video was of interest to me

The information in this video is likely to improve my clinical practice or research

I would recommend this video to my colleagues
Published: 8 Jul 2009
Views: 15730
Rating:
Save
Dr Paul Bunn - University of Colorado, Denver, USA
erlotininb, cetuximab or gefitinib for lung cancer in pill form- less toxic and better tolerated, better survival for patients with EGFR gene mutation.

Related Videos

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
23 Sep 2021
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity
Dr Danny Nguyen - City of Hope, Orange County, USA
Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )
21 Sep 2021
Oncogenesis: Lung cancer
Dr Edgardo Santos - Florida Precision Oncology, GenesisCare, Florida, USA
Oncogenesis: Lung cancer ( Dr Edgardo Santos - Florida Precision Oncology, GenesisCare, Florida, USA )
28 Jul 2021
Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC a...
Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China
Unmet medical needs and emerging data on EGFR exon 20 insertion mutation NSCLC at ASCO 2021 ( Prof Caicun Zhou - Shanghai Pulmonary Hospital, Shanghai, China )
16 Jul 2021
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNS...
Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC ( Dr Alex Spira - Virginia Cancer Specialists Research Institute, Fairfax, USA )
6 Jul 2021
Latest updates in exon 20 insertions focusing on targeted therapies, novel appro...
Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho
Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )
22 Jun 2021
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
16 Apr 2021
First-line pembrolizumab plus chemotherapy for patients with advanced squamous N...
Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General H...
First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )
9 Apr 2021
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
9 Apr 2021

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation